Evgeny Zaytsev

NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.

InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.

Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA.

Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA.

Asset Management Co. is a venture capital firm. The company was founded in 1965 and is headquartered in East Palo Alto, CA.

NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.

NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND.